Xiamen Amoytop Biotech Co., Ltd.
Clinical trials sponsored by Xiamen Amoytop Biotech Co., Ltd., explained in plain language.
-
Weekly shot could replace daily needles for short kids
Disease control Recruiting nowThis study tests a new growth hormone medicine (inpegsomatropin) given once a week compared to the standard daily growth hormone shot. About 300 children with idiopathic short stature (short for no known medical reason) will receive either the weekly or daily injection for one ye…
Phase: PHASE3 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Weekly shot may replace daily injections for growth in SGA kids
Disease control Recruiting nowThis study tests a new growth hormone medicine (inpegsomatropin) given once a week, compared to the standard daily growth hormone shot, in 141 children born small for gestational age who are shorter than average. The goal is to see if the weekly shot works as well or better at he…
Phase: PHASE3 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New hope for rare blood disorder: experimental drug targets patients failed by standard therapy
Disease control Recruiting nowThis study tests two doses of peginterferon alfa-2b in 27 adults with essential thrombocythemia (a rare blood disorder causing too many platelets) who either didn't respond to or couldn't tolerate the standard drug hydroxyurea. Participants receive injections for up to 96 weeks, …
Phase: PHASE2 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 03, 2026 12:04 UTC